Patents Assigned to Adamas Pharma, LLC
  • Patent number: 12233033
    Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: February 25, 2025
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Timothy J. Fultz, Sangita Ghosh, Natalie McClure
  • Patent number: 11903908
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: February 20, 2024
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Timothy J. Fultz, Natalie McClure
  • Patent number: 11197835
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: December 14, 2021
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Patent number: 11077073
    Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 3, 2021
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Timothy J. Fultz, Sangita Ghosh, Natalie McClure
  • Patent number: 11065213
    Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: July 20, 2021
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Timothy J. Fultz, Sangita Ghosh, Natalie McClure
  • Patent number: 10646456
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 12, 2020
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Timothy J. Fultz, Natalie McClure
  • Patent number: 10154971
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: December 18, 2018
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Timothy J. Fultz, Natalie McClure
  • Publication number: 20180263928
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: May 21, 2018
    Publication date: September 20, 2018
    Applicant: Adamas Pharma, LLC
    Inventors: Gregory T. WENT, Gayatri SATHYAN, Kavita VERMANI, Gangadhara GANAPATI, Michael COFFEE, Efraim SHEK, Ashok KATDARE
  • Patent number: 9877933
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: January 30, 2018
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Patent number: 9867792
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: January 16, 2018
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Patent number: 9867793
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 16, 2018
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Patent number: 9867791
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: January 16, 2018
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare